Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma
Condition(s):Urothelial Carcinoma; Bladder Cancer; Transitional Cell CarcinomaLast Updated:December 5, 2023Terminated
Hide Studies Not Open or Pending
Condition(s):Urothelial Carcinoma; Bladder Cancer; Transitional Cell CarcinomaLast Updated:December 5, 2023Terminated
Condition(s):Uterine Cervical Neoplasms; Cancer of Cervix; Cervical Cancer; Cervical Neoplasms; Uterine Cervical Cancer; Cancer of the Uterine CervixLast Updated:May 6, 2023Not yet recruiting
Condition(s):Gastric AdenocarcinomaLast Updated:April 5, 2023Recruiting
Condition(s):Recurrent High Grade Uterine CancerLast Updated:January 17, 2024Not yet recruiting
Condition(s):Solid TumorLast Updated:July 29, 2021Completed
Condition(s):Metastatic Breast CancerLast Updated:February 23, 2017Completed
Condition(s):Recurrent or Metastatic Breast CancerLast Updated:February 16, 2024Completed
Condition(s):Locally Advanced Cancer; Cervical CancerLast Updated:September 11, 2023Active, not recruiting
Condition(s):Metastatic Breast CancerLast Updated:January 25, 2023Active, not recruiting
Condition(s):Urethral Stricture, MaleLast Updated:November 8, 2023Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.